PIK3CD and B-cell chronic lymphocytic leukemia: Idelalisib is the frst FDA-approved PI3K inhibitor for use in combination with rituximab for the treatment of relapsed or refractory chronic lymphocytic leukemia, or as monotherapy for relapsed small lymphocytic lymphoma and follicular lymphoma previously treated with two or more prior systemic therapies.